A Study to Investigate the Safety, Tolerability, Food Effect, Pharmacokinetics and Pharmacodynamics of FOR-6219
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, Phase I/Ib study which will assess
the safety, tolerability, food effect, pharmacokinetics and pharmacodynamics of FOR-6219, a
hydroxysteroid (17B) dehydrogenase (HSD17B1) inhibitor. The study will be performed in three
parts: (I) Single ascending doses (SAD) in healthy post-menopausal women; (II) multiple
ascending doses (MAD) in post-menopausal women; (III) multiple ascending doses in healthy
pre-menopausal women.